Topic Code
HORIZON-HLTH-2025-03-DISEASE-02-two-stage
F&T Portal
Call Identifier
HORIZON-HLTH-2025-03
Two stage (2025) — Stage 2
Instrument
HORIZON-RIA
Research and Innovation Action
Budget Model
Lump Sum
HORIZON-AG-LS
Funding Rate
100%
Annex G — RIA = 100%
Page Limit (Part B)
45 pages
RIA + lump sum — Stage 2
Evaluation Thresholds
4 / 4 / 4 · cum. 12
Non-standard — Stage 2 override
Expected Projects
7
€6–8M per project (WP stated)
Destination
Tackling diseases and reducing disease burden
WP Part 4 (2025)
Cluster / Pillar
Cluster 1 / Pillar II
Health
China Eligibility
Eligible ✓
2025 WP: no RIA restriction
Special Conditions
Two-stage [Stage 2]
Stage 1: 16 Sep 2025 (closed)
This is a two-stage topic (Stage 2). Stage 1 closed 16 September 2025. Stage 2 deadline: 16 April 2026. Stage 1 page limit: 10 pages. Stage 2 page limit: 45 pages. Blind evaluation pilot applies to Stage 1.
This topic uses non-standard evaluation thresholds: Stage 2: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
Communication networks restriction: Entities assessed as high-risk suppliers of mobile network communication equipment (and entities they own or control) are not eligible to participate in this topic.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.
Mandatory annex: Proposals under this topic are expected to include clinical studies. Applicants should provide details in the dedicated annex using the template provided in the submission system.
Expected Outcomes
- The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at achieving a lasting benefit.
- The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond.
- The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR principles, thereby encouraging further use of the data.
- Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
- Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.
Want the full analysis?
The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.
Compliance traps
Scoring playbook
Consortium blueprint
Positioning guide
Red flags
Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day